Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-167,307
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
L-167,307 (sometimes referred to as L'167 in specific research contexts) is a potent, orally active, and highly selective non-peptide antagonist of the **neurokinin-1 (NK1) receptor**. Developed by Merck, it was designed to inhibit the binding of substance P, a neuropeptide involved in the transmission of pain signals and the mediation of inflammatory responses. By blocking the NK1 receptor, L-167,307 demonstrates significant central nervous system (CNS) penetration and has been primarily investigated for its potential therapeutic applications in treating chemotherapy-induced nausea and vomiting (CINV), depression, and various pain disorders. Its development was part of a broader program at Merck that eventually led to the approval of related NK1 antagonists like aprepitant.
- Other names
- L-167,307
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on L-167,307.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-167,307.